Vericel AI Stock Analysis
Want to see VCEL full AI Analyst Report?
Vericel (VCEL) AI Stock Analysis
Vericel
(NASDAQ:VCEL)
The score is driven primarily by improving financial performance (profitability inflection, strong margins, positive cash generation) and a very positive earnings call with raised guidance. These positives are moderated by elevated valuation (high P/E, no yield) and technical overbought signals despite a strong uptrend.
Vericel (VCEL) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $3.03B
- Dividend Yield
- ―
- Average Volume (3M)
- 638.01K
- Price to Earnings (P/E)
- 90.1
- Beta (1Y)
- 0.35
- Revenue Growth
- 25.30%
- EPS Growth
- 147.62%
- Country
- US
- Employees
- 398
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Vericel Business Overview & Revenue Model
Company Description
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine...
How the Company Makes Money
Vericel primarily makes money by selling its FDA-approved and marketed therapies and related services to hospitals, burn centers, and orthopedic/sports medicine providers, generating product revenue when its products are ordered and used for patient...
Vericel Earnings Call Summary
The call conveyed strong positive momentum across both commercial franchises, with record revenue, substantial profitability and free cash flow growth, repeated guidance increases, expanding MACI adoption, and improving burn care execution. Management also highlighted multiple 2027 and longer-term growth drivers. The main challenges were the inherent variability of Epicel and the lack of formal 2027 guidance, but these were outweighed by the reported operating and financial performance.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Vericel raised full-year total revenue guidance to $344 million-$346 million, representing 25% revenue growth for the year at the midpoint and an increase in revenue guidance of nearly $25 million since the start of the year; full-year MACI revenue guidance increased to $290 million-$292 million, with fourth-quarter MACI guidance of 21% growth, or approximately $102 million of revenue at the midpoint, with upside if recent trends continue into December; full-year burn care revenue guidance increased to approximately $54 million, implying $12 million of total fourth-quarter burn care revenue, including $9 million of Epicel and commercial NexoBrid revenue and $3 million of NexoBrid BARDA procurement revenue; full-year gross margin is expected to be approximately 75%, and full-year adjusted EBITDA margin guidance increased to approximately 28% from 27%; the company expects another $3 million of BARDA procurement revenue in the fourth quarter and about $4 million to start next year in the first quarter, with opportunities for further procurement later in the year, remains on track for a potential MACI U.K. launch in the second half of 2027, and expects to reach the high 30% range for adjusted EBITDA margin over the next few years.
Vericel Financial Statement Overview
Summary
Financial statements show a transition to profitability with strong gross margins (~75% TTM) and positive operating/free cash flow, alongside manageable leverage. Key offsets are the slowdown in TTM revenue growth and some free-cash-flow volatility noted in the cash flow analysis.
Income Statement
78PositiveBalance Sheet
74PositiveCash Flow
71Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 324.17M | 276.26M | 237.22M | 197.52M | 164.37M | 156.18M |
| Gross Profit | 241.41M | 205.60M | 172.11M | 135.58M | 109.79M | 106.03M |
| EBITDA | 48.58M | 30.29M | 16.63M | 2.86M | -11.64M | -4.61M |
| Net Income | 33.31M | 16.52M | 10.36M | -3.18M | -16.71M | -7.47M |
Balance Sheet | ||||||
| Total Assets | 517.11M | 487.97M | 432.72M | 353.66M | 273.00M | 243.71M |
| Cash, Cash Equivalents and Short-Term Investments | 170.27M | 137.50M | 116.21M | 109.56M | 119.54M | 103.40M |
| Total Debt | 91.15M | 98.27M | 98.85M | 88.04M | 47.57M | 50.18M |
| Total Liabilities | 132.94M | 133.33M | 140.75M | 127.70M | 80.73M | 73.24M |
| Stockholders Equity | 384.17M | 354.64M | 291.97M | 225.95M | 192.27M | 170.46M |
Cash Flow | ||||||
| Free Cash Flow | 45.87M | 24.75M | -5.81M | 7.80M | 10.09M | 21.13M |
| Operating Cash Flow | 65.31M | 51.91M | 58.16M | 35.31M | 17.69M | 29.04M |
| Investing Cash Flow | -26.12M | -43.94M | -79.03M | -3.13M | -36.21M | -3.50M |
| Financing Cash Flow | -6.10M | 7.07M | 19.05M | 3.62M | 1.04M | 9.17M |
Vericel Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VCEL, the sentiment is Positive. The current price of 59.45 is above the 20-day moving average (MA) of 44.51, above the 50-day MA of 41.75, and above the 200-day MA of 39.08, indicating a bullish trend. The MACD of 3.69 indicates Negative momentum. The RSI at 82.28 is Negative, neither overbought nor oversold. The STOCH value of 95.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VCEL.
Vericel Risk Analysis
Vericel disclosed 66 risk factors in its most recent earnings report. Vericel reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksVericel Peers Comparison
Overall Rating
- VCEL70Outperform
MESO62Neutral
PROK48Neutral
RARE48Neutral
PGEN46Neutral
SANA44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| VCEL | 70Outperform | $3.01B | 90.08 | 9.09% | ― | 25.30% | 147.62% |
| MESO | 62Neutral | $1.85B | -30.92 | -10.06% | ― | 600.89% | 47.33% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| PROK | 48Neutral | $335.63M | -1.98 | 8.83% | ― | 55.22% | 2.13% |
| RARE | 48Neutral | $1.65B | -3.22 | 213.22% | ― | 15.76% | 12.63% |
| PGEN | 46Neutral | $1.62B | 69.11 | 57.93% | ― | 2387.61% | ― |
| SANA | 44Neutral | $728.11M | -4.32 | -97.08% | ― | ― | 45.15% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VCEL | Vericel Corporation | 59.45 | 19.61 | 49.22% | |
| MESO | Mesoblast | 13.65 | -1.27 | -8.51% | |
| PGEN | Precigen, Inc. | 4.72 | 0.86 | 22.28% | |
| RARE | Ultragenyx Pharmaceutical, Inc. | 16.70 | -16.20 | -49.24% | |
| SANA | Sana Biotechnology, Inc. | 2.29 | -1.37 | -37.43% | |
| PROK | Prokidney Corp. | 1.13 | -1.15 | -50.44% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026